curve.gif (1916 bytes)

header-large1.gif (13991 bytes)

header-large2.gif (16324 bytes) curve4.gif (1967 bytes)
filler.gif (49 bytes) filler.gif (49 bytes) filler.gif (49 bytes)
 

 

 

 

 

 

 

filler.gif (49 bytes)

MTA Agreement

filler.gif (49 bytes)
filler.gif (49 bytes)

Corporate & Venture Development (CVD) serves Duke University and its Medical Center, a top-ten research university located in Durham, North Carolina.  CVD is responsible for commercially-sponsored research, patents and licenses, new venture activity, corporate gifts, and corporate vending relationships.  Corporate & Venture Development includes:
 

  • Vice Chancellor Corporate & Venture Development
  • Office of Licensing & Ventures
  • Office of Corporate Research Collaborations
  • Corporate Alliances & Development
  • Corporate Programs

CClick here for:  Office of Licensing & Ventures (Tech Transfer)

Staff of Corporate and Venture Development (CVD)

Robert L. Taber, Ph.D., Vice Chancellor for Corporate and Venture Development at Duke University Medical Center and Health System, heads the Offices of Technology Licensing and Venture Development, and Corporate Research Collaborations.    The former Office is responsible for patents and licenses and new venture activity for the University as a whole, and the latter for commercially sponsored research, corporate gifts, and selected corporate vending relationships for the Duke School of Medicine and the Health System in particular.

 Dr. Taber obtained his B.A. from Harpur College, S.U.N.Y. in 1964, his Ph.D. from the University of Pittsburgh School of Medicine in 1969 and went on to a post-doctoral fellowship at MIT with Dr. David Baltimore. He then joined the Microbiology faculty of the University of Massachusetts School of Medicine at its formation, as an Assistant Professor (1971-1973).  In 1973 he moved to Roswell Park Memorial Institute as a Senior Cancer Research Scientist (tenured) while holding an adjunct appointment in Microbiology at the State University of New York at Buffalo.   In 1979 he left to become Associate Director of the Northern California Cancer Program (the National Cancer Institute Bay Area Cancer Center) based at Stanford and had an adjunct appointment and laboratory in the Department of Pharmacology at the University of California School of Medicine, San Francisco.

 Dr. Taber left academics in 1981 to participate in the founding of Integrated Genetics, Inc. in Framingham MA as Vice President, Corporate Development.  The company was based on DNA technology for both diagnostic and therapeutic applications and went through two private venture and two public rounds of financing by 1985.  The company was subsequently acquired by Genzyme.

 In 1985, Taber was recruited to become President and CEO of EG&G MRI, based in Worcester, MA, a division of EG&G, Inc. (now PerkinElmer, Inc.), EG&G at the time was an instrument and government services company with ~$3B in sales. His division performed biomedical testing for the biotechnology industry, NIH and the military.  During Taber’s tenure with the company, the division he led doubled in sales to about $20,000,000 with 220 employees while maintaining consistent profitability. The division was subsequently acquired by Charles River Laboratories. During that time as President of EG&G MRI he also maintained an office at corporate headquarters and worked with both (1) EG&G Ventures, an internal fund for strategic start-up investment and (2) Corporate Business Development where he participated in initiatives that subsequently generated billions of government revenue to the Corporation.

 In 1990, Dr. Taber left EG&G to be a founder, as President and CEO of One Cell Systems, an analytic device company based on MIT technology for cellular analysis and separation.  The company is still in business in Cambridge, MA.

 In late 1992, he was recruited to Duke University Medical Center as an Associate Vice Chancellor to assume responsibility for patent and licensing activities for the whole University.  Over the course of the next few years he acquired additional responsibility for new venture development, selected international initiatives, commercial agreements and selected vending relationships.   He was promoted to a Vice Chancellor level position in 1998.

  

Robert L. Taber, Ph.D.
919-684-3628
taber002@mc.duke.edu

taber.jpg (5325 bytes)

Rose Ritts, PhD, is the Executive Director of Duke’s Office of Licensing & Ventures. With a demonstrated track record of new product and business development in biotechnology, medical devices, and high-tech markets across startup, corporate and government environments, Dr. Ritts oversees the licensing and ventures operations of Duke University and Duke Medical Center with an emphasis on a proactive approach to licensing, new company formation and technology development. Her experience includes designing implantable devices; serving as a program manager for biowarfare defense systems at DoD's Defense Advanced Research Projects Agency; managing a biotechnology and materials business unit within a large New Jersey corporation; performing IP and technical due diligence as a consultant to venture capital firms; and most recently as founder and CEO of a venture-capital-funded biotech startup, PowerZyme Inc, in Princeton, New Jersey. Ritts received her BS in biomedical engineering from Duke, her MS and PhD from Stanford in electrical engineering, and graduated from Stanford's Entrepreneurial Executive Management Program.

 


Rose Ritts, PhD
Executive Director
919-681-6412

urose.ritts@duke.edu

www.olv.duke.edu

rose.jpg (5000 bytes)

 

 

Dr. Smith holds responsibility for all of the Duke Medical School's research-related interactions with commercial entities including clinical trials, non-clinical sponsored research, material transfers, and other related endeavors. Dr. Smith also has intellectual property management responsibilities, particularly in the context of that arising from, or closely associated with, commercially sponsored research projects.

Prior to joining Duke in 1994, Dr. Smith had spent over twelve years in various corporate R&D; research and management positions, including in the TSI Corporation R&D; Division, the EG&G; Mason Research Institute, and at GTE Laboratories. His military service was as an Army intelligence officer stationed at the U.S. Army Foreign Science and Technology Center.

Dr. Smith received his Ph.D. in biochemistry from the University of Virginia. He also holds an M.S. in organic chemistry from Northwestern University, and a B.S. in chemistry from Washington and Lee University. His postdoctoral experience includes research at the Institute for Neurobiology in Jülich, Germany, the Department of Physiology at Washington University, and the Marine Biological Laboratory, Woods Hole. Dr. Smith holds four patents and is the author of numerous scientific publications. He is a member of Phi Beta Kappa and Sigma Xi.


H. Gilbert Smith, Ph.D.
919-681-6497
smith087@mc.duke.edu

smith_s.jpg (11915 bytes)

Mr. Herosian holds a BA in Economics and a BS in Biology from Tufts University, as well as an MBA from Rutgers. Prior to joining Duke, he was the founder of a successful Research Triangle Park based technology company. While leading the company, Alan successfully secured venture capital financing totaling $10 million, effectively obtained and linked proprietary technologies via acquisition and licensing agreements and positioned the company for its successful Initial Public Offering. Mr. Herosian is also a veteran of the biotechnology industry, having held various executive positions with two major pharmaceutical companies. As Director, Corporate Alliances & Development, he is actively involved in many facets of corporate partnering and business development at Duke University Medical Center and throughout the Duke Health System.

 


Alan Herosian, M.B.A.
919-419-4636
heros001@mc.duke.edu

herosian.jpg (6150 bytes)

Mr. Freck holds an MBA from the Fuqua School of Business at Duke University and an AB in history from Princeton University. His career in health care began in 1992 with the SunHealth Corporation where he analyzed and managed network development and contract negotiation projects for partner hospitals. In 1994, he came to the Duke University Medical Center to join the Network Services and Contracting division, focusing on managed care contract business development and negotiations. In his seven years in managed care at DUMC, he developed Duke's portfolio of specialty network contracts, pharmacy benefit management contracts, and managed special case price negotiations for cardiovascular and transplant services. In April 2001, he joined OST as an Associate Director in Corporate Programs.

 



Dean A. Freck, M.B.A
919-419-5031
freck001@mc.duke.edu
Mitch Dozier, MBA, is the Director of Operations & Finance for Corporate & Venture Development and the Office of Licensing & Ventures. Previously, he worked as a management consultant with Andersen Consulting and Premier and as an internal consultant with Duke University Health System. In a variety of organizations, he has led efforts in process design, quality improvement, strategic planning, new product development, software development, marketing, decision support, balanced scorecards, budget management, cost accounting and customer service. Dozier received his MBA from the Fuqua School of Business at Duke University and a BS in Business (Finance) from the University of North Carolina, Chapel Hill.
Mitch Dozier, MBA
Business Manager  919-681-7591

mitch.dozier@duke.edu

mitch.jpg (4731 bytes)

 

 

 

curve3.gif (1965 bytes)

© Copyright 2000 Office of Science and Technology
Last Modified:  Thursday, February 07, 2008 10:46:36 AM
Questions or Comments should be emailed to the Webmaster

curve2.gif (2004 bytes)